Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

18,000

Employees18,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

18,000

Employees18,000

GILD Key Statistics

Market cap

137.61B

Market cap137.61B

Price-Earnings ratio

293.50

Price-Earnings ratio293.50

Dividend yield

2.76%

Dividend yield2.76%

Average volume

8.94M

Average volume8.94M

High today

$111.24

High today$111.24

Low today

$108.43

Low today$108.43

Open price

$110.71

Open price$110.71

Volume

5.91M

Volume5.91M

52 Week high

$112.11

52 Week high$112.11

52 Week low

$62.07

52 Week low$62.07

GILD News

TipRanks 2d

Gilead announces European Medicines Agency validation for lenacapavir

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization application and E...

TipRanks 3d

Optimistic Buy Rating for Gilead Sciences Driven by Anticipated FDA Approval and Strategic Market Positioning

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Terence Flynn from Morgan Sta...

Analyst ratings

64%

of 33 ratings

Buy

63.6%

Hold

33.3%

Sell